Hansa Biopharma AB (OSTO:HNSA)
kr 40.5 3 (8%) Market Cap: 2.66 Bil Enterprise Value: 3.06 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 77/100

Hansa Biopharma AB at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2021 / 03:44PM GMT
Release Date Price: kr122.5 (-6.95%)
James Quigley;SÃ;ren Tulstrup
Morgan Stanley - Analyst;Hansa Biopharma AB -

Great. So, good morning and good afternoon, everyone. I'm James Quigley, European pharma and biotech analyst at Morgan Stanley. It is my pleasure to welcome you all to this session with Hansa Biopharma. Today we're joined by Søren Tulstrup, the CEO. (Conference Instructions).

From a disclosure point of view, so for important disclosures, please see the Morgan Stanley research disclosure website, www.MorganStanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales rep.

So, with all that explained, I think we can jump straight in. So, to start with the story, could you just give us a bit of an introduction to Hanson's platform and how your approach differs from other novel mechanisms to treat people with autoimmune diseases as well, so like antibodies, plasma exchange, FcRn to -- just to sort of set the scene about that platform?

¸

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot